Ikarian Capital’s Neurocrine Biosciences NBIX Stock Holding History

Ikarian Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-54,062	Closed	-$7.67M	–	195
2025 Q4	$7.67M	Buy	+54,062	New	+$7.83M	0.6%	48
2024 Q3	–	Sell	-40,000	Closed	-$5.51M	–	165
2024 Q2	$5.51M	Buy	+40,000	New	+$5.49M	0.96%	29
2022 Q3	–	Sell	-38,600	Closed	-$3.76M	–	146
2022 Q2	$3.76M	Buy	+38,600	New	+$3.56M	0.69%	44

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's NBIX Position: Q1 2026 in Review

Ikarian Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 54,062 shares — an estimated $7.67M sold.

Ikarian Capital first reported a position in NBIX in Q2 2022 and held it in 3 quarters. The position peaked at $7.67M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Ikarian Capital reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Ikarian Capital sold 54,062 Neurocrine Biosciences shares in Q1 2026, an estimated $7.67M.
Ikarian Capital first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 3 quarters.
Ikarian Capital's Neurocrine Biosciences position peaked at $7.67M in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.